Statin therapy and SAR-COV-2: an available and potential therapy?

Eur Heart J Cardiovasc Pharmacother. 2020 Sep 1;6(5):333-334. doi: 10.1093/ehjcvp/pvaa050.

Authors

Rania G Abdel-Latif¹, Shaban Mohammed², Islam Y Elgendy³

Affiliations

¹ Department of Pharmacology and Toxicology, Faculty of Pharmacy, Minia University, El-Minia, Egypt.
² Department of Pharmacy, Hamad Medical Corporation, Doha, Qatar.
³ Division of Cardiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.

No abstract available

Publication types

Letter

MeSH terms

Animals
Antiviral Agents / therapeutic use*
Betacoronavirus / drug effects*
Betacoronavirus / immunology
Betacoronavirus / pathogenicity
COVID-19
COVID-19 Drug Treatment
Coronavirus Infections / drug therapy*
Coronavirus Infections / immunology
Coronavirus Infections / virology
Host-Pathogen Interactions
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Pandemics
Pneumonia, Viral / drug therapy*
Pneumonia, Viral / immunology
Pneumonia, Viral / virology
SARS-CoV-2

Substances

Antiviral Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors